These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6678835)

  • 1. Single administration of atenolol does not influence the kinetics of orally given isosorbide dinitrate.
    Bogaert MG; Rosseel MT; Bruyneel K
    Int J Clin Pharmacol Res; 1983; 3(6):491-3. PubMed ID: 6678835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of isosorbide dinitrate and mononitrates after acute and chronic oral administration of isosorbide dinitrate in man.
    Bruyneel K; Rosseel MT; Bogaert MG
    Arzneimittelforschung; 1982; 32(7):769-73. PubMed ID: 6889879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of exercise on plasma concentrations of isosorbide dinitrate.
    Bogaert MG; Lefebvre RA; Rosseel MT; Bouckaert J
    Eur J Clin Pharmacol; 1988; 35(2):213-5. PubMed ID: 3191942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of isosorbide dinitrate and the isosorbide mononitrates after increasing doses of a retard preparation of isosorbide dinitrate.
    Bogaert MG; Rosseel MT
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2424-7. PubMed ID: 7422532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
    Laufen H; Aumann M; Leitold M
    Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
    Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
    Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
    Menke G; Schnellhammer R; Rietbrock N
    Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fate of orally given isosorbide dinitrate in man: factors of variability.
    Bogaert MG; Rosseel MT
    Z Kardiol; 1983; 72 Suppl 3():11-3. PubMed ID: 6141676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
    Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
    Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fate of isosorbide dinitrate and mononitrates in patients with renal failure.
    Bogaert MG; Rosseel MT; Boelaert J; Daneels R
    Eur J Clin Pharmacol; 1981; 21(1):73-6. PubMed ID: 7333349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fate of orally given isosorbide dinitrate in cirrhotic patients.
    Bogaert MG; Rosseel MT; Elewaut A
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):491-2. PubMed ID: 6500768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects.
    Chasseaud LF; Down WH; Grundy RK
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):157-60. PubMed ID: 1233213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
    Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
    J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
    Chasseaud LF; Doyle E; Taylor T; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of pharmacokinetic interaction between isosorbide dinitrate and the beta-adrenergic receptor blockers atenolol and propranolol.
    Bogaert MG; Rosseel MT; Lefebvre RA
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):90S-91S. PubMed ID: 6743478
    [No Abstract]   [Full Text] [Related]  

  • 17. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations.
    Laufen H; Schmid M; Leitold M
    J Pharm Sci; 1983 May; 72(5):496-9. PubMed ID: 6864494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of electric foot shock on pharmacokinetics of isosorbide dinitrate orally administered to rats.
    Gomita Y; Furuno K; Araki Y
    Jpn J Pharmacol; 1989 Feb; 49(2):297-9. PubMed ID: 2733266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine].
    Blasini R; Brügmann U; Reiniger G; Rudolph W
    Herz; 1985 Jun; 10(3):163-71. PubMed ID: 3926613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.